Tirzepatide Explored for Liver Health in Obese Patients with MASLD

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is the most prevalent cause of chronic liver disease globally, disproportionately affecting individuals with overweight, obesity, type 2 diabetes, and cardiovascular disease. Tirzepatide, a dual GLP-1 and GIP receptor agonist, is an established treatment for type 2 diabetes and obesity, and has shown preliminary promise in improving MASLD markers. This pilot study aims to specifically investigate the effects of tirzepatide on liver health parameters in patients diagnosed with both MASLD and obesity, addressing a critical knowledge gap in targeted MASLD therapies.

As this is a recruiting pilot study, specific results are not yet available. However, the study aims to identify significant improvements in markers associated with MASLD following Tirzepatide treatment. Researchers anticipate observing a reduction in liver fat content, as quantified by ultrasound, and improvements in liver enzyme levels such as alanine aminotransferase (ALT) and aspartate aminotransferase (AST) from blood tests, indicating reduced liver inflammation. > The primary objective is to determine if Tirzepatide can effectively reduce liver steatosis and improve liver function, thereby demonstrating a beneficial impact on MASLD progression in obese individuals. These findings are expected to support Tirzepatide's potential as a therapeutic option for this widespread chronic liver condition, providing crucial preliminary data on its efficacy in mitigating liver damage and inflammation.